In preclinical models and cancer patients, blocking interactions of PD-1 with PD-L1 augments the effector function of PD-1+ exhausted CTLs, and induces the expansion of TCF1+ progenitor-like exhausted T cells with self-renewal capacity (16). Here, PDCD1 is linked to cancer.